PUNE, India, September 9, 2016 /PRNewswire/ --
RnRMarketResearch.com adds "Anaplastic Thyroid Cancer - Pipeline Review,H2 2016" market research report with comprehensive information on the therapeutic development for Anaplastic Thyroid Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route
Complete report on H2 2016 pipeline review of Anaplastic Thyroid Cancer with 23 market data tables and 14 figures, spread across 73 pages is available at http://www.rnrmarketresearch.com/anaplastic-thyroid-cancer-pipeline-review-h2-2016-market-report.html .
Anaplastic thyroid cancers are undifferentiated tumors of the thyroid follicular epithelium. Symptoms include cough, coughing up blood, difficulty swallowing, loud breathing and hoarseness or changing voice.
The report also reviews key players involved in the therapeutic development for Anaplastic Thyroid Cancer and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Companies discussed in this Anaplastic Thyroid Cancer Pipeline Review, H2 2016 report include Daiichi Sankyo Company, Limited, Genelux Corporation, Immune Pharmaceuticals Inc., Millennium Pharmaceuticals Inc, Novartis AG, Pfizer Inc., Plexxikon Inc. and Trophogen, Inc. Drug Profiles mentioned in this research report are ceritinib, CLM-3, crizotinib, crolibulin, ,dabrafenib mesylate + trametinib dimethyl sulfoxide, efatutazone, GLONC-2, GLV-1h153, pexidartinib, PLX-8394, Recombinant Protein to Antagonize VEGF and PDGF for Anaplastic Thyroid Cancer and Wound Healing, sapanisertib and utomilumab.
Order a copy of this report @ http://www.rnrmarketresearch.com/contacts/purchase?rname=674809 .
Scope of this report: The report provides a snapshot of the global therapeutic landscape of Anaplastic Thyroid Cancer and reviews pipeline therapeutics for Anaplastic Thyroid Cancer by companies and universities/research institutes based on information derived from company and industry-specific sources and key players involved Anaplastic Thyroid Cancer therapeutics and enlists all their major and minor projects. The research covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages. The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities and assesses Anaplastic Thyroid Cancer therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report summarizes all the dormant and discontinued pipeline projects with latest news related to pipeline therapeutics for Anaplastic Thyroid Cancer.
Another newly published market research report titled on Chemotherapy Induced Neutropenia - Pipeline Review, H2 2016 provides comprehensive information on the therapeutic development for Chemotherapy Induced Neutropenia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Chemotherapy Induced Neutropenia and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development are Apotex Inc., Biocon Limited, Biogenomics Limited, Bolder Biotechnology, Inc., Cellerant Therapeutics, Inc., Chong Kun Dang Pharmaceutical Corp., Cinfa Biotech S.L., Dr. Reddy's Laboratories Limited, Gene Techno Science Co., Ltd., Generon (Shanghai) Corporation Ltd., Genexine, Inc., Hanmi Pharmaceuticals, Co. Ltd., Myelo Therapeutics GmbH, Octapharma AG, Pfenex Inc., Pfizer Inc., Reliance Life Sciences Pvt. Ltd., Richter Gedeon Nyrt., Sandoz International GmbH and USV Limited. Chemotherapy Induced Neutropenia Pipeline market research report of 104 pages is available at http://www.rnrmarketresearch.com/chemotherapy-induced-neutropenia-pipeline-review-h2-2016-market-report.html .
Explore more reports on Cancer Therapeutics .
RnRMarketResearch.com is your single source for all market research needs. Our database includes 500,000+ market research reports from over 100+ leading global publishers & in-depth market research studies of over 5000 micro markets. With comprehensive information about the publishers and the industries for which they publish market research reports, we help you in your purchase decision by mapping your information needs with our huge collection of reports.
Contact: Ritesh Tiwari UNIT no 802, Tower no. 7, SEZ Magarpatta city, Hadapsar Pune - 411013 Maharashtra, India. Tel: +1-888-391-5441 email@example.com
Connect with Us:
G+ / Google Plus: https://plus.google.com/104156468549256253075/posts
RSS / Feeds: http://www.rnrmarketresearch.com/feed
SOURCE RnR Market Research
Subscribe to our Free Newsletters!
Drug hypersensitivity is an adverse reaction that occurs due to an interaction between a drug and ...
Stiff joints are a major problem for the elderly, as the joints tend to wear-and-tear with ...
Uterine/Endometrial cancer is the sixth most common cancer in women worldwide. Uterine cancer ...View All